There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and BioMarin Pharmaceutical (BMRN) with bullish sentiments.
Boston Scientific (BSX)
Credit Suisse analyst Matt Miksic reiterated a Buy rating on Boston Scientific today and set a price target of $47.00. The company’s shares closed last Wednesday at $39.59.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of 10.3% and a 69.0% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $45.85.
See today’s analyst top recommended stocks >>
BioMarin Pharmaceutical (BMRN)
Credit Suisse analyst Martin Auster maintained a Buy rating on BioMarin Pharmaceutical today and set a price target of $128.00. The company’s shares closed last Wednesday at $77.90.
According to TipRanks.com, Auster is a 5-star analyst with an average return of 15.1% and a 55.6% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.
Currently, the analyst consensus on BioMarin Pharmaceutical is a Moderate Buy with an average price target of $129.95, a 51.4% upside from current levels. In a report issued on August 5, Piper Sandler also maintained a Buy rating on the stock with a $133.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
